133 related articles for article (PubMed ID: 24700299)
1. The frequencies and clinical implications of mutations in 33 kinase-related genes in locally advanced rectal cancer: a pilot study.
Abdul-Jalil KI; Sheehan KM; Toomey S; Schmid J; Prehn J; O'Grady A; Cummins R; O'Neill B; McNamara DA; Deasy J; Breathnach O; Grogan L; Rogers A; Doherty G; Winter D; Ryan J; El-Masry S; Gibbons D; Sheahan K; Gillen P; Kay EW; Hennessy BT
Ann Surg Oncol; 2014 Aug; 21(8):2642-9. PubMed ID: 24700299
[TBL] [Abstract][Full Text] [Related]
2. Predicting pathological response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer using 18FDG-PET/CT.
Shanmugan S; Arrangoiz R; Nitzkorski JR; Yu JQ; Li T; Cooper H; Konski A; Farma JM; Sigurdson ER
Ann Surg Oncol; 2012 Jul; 19(7):2178-85. PubMed ID: 22395978
[TBL] [Abstract][Full Text] [Related]
3. Preoperative chemoradiotherapy improves local recurrence free survival in locally advanced rectal cancer.
Tural D; Ozturk M; Selcukbiricik F; Yildiz O; Elicin O; Turna H; Guney S; Ozguroglu M
J BUON; 2013; 18(2):385-90. PubMed ID: 23818350
[TBL] [Abstract][Full Text] [Related]
4. Oncologic outcomes after neoadjuvant chemoradiation followed by curative resection with tumor-specific mesorectal excision for fixed locally advanced rectal cancer: Impact of postirradiated pathologic downstaging on local recurrence and survival.
Kim NK; Baik SH; Seong JS; Kim H; Roh JK; Lee KY; Sohn SK; Cho CH
Ann Surg; 2006 Dec; 244(6):1024-30. PubMed ID: 17122629
[TBL] [Abstract][Full Text] [Related]
5. Selective lateral pelvic lymph node dissection in patients with advanced low rectal cancer treated with preoperative chemoradiotherapy based on pretreatment imaging.
Akiyoshi T; Ueno M; Matsueda K; Konishi T; Fujimoto Y; Nagayama S; Fukunaga Y; Unno T; Kano A; Kuroyanagi H; Oya M; Yamaguchi T; Watanabe T; Muto T
Ann Surg Oncol; 2014 Jan; 21(1):189-96. PubMed ID: 23963871
[TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant chemoradiotherapy affects the indications for lateral pelvic node dissection in mid/low rectal cancer with clinically suspected lateral node involvement: a multicenter retrospective cohort study.
Oh HK; Kang SB; Lee SM; Lee SY; Ihn MH; Kim DW; Park JH; Kim YH; Lee KH; Kim JS; Kim JW; Kim JH; Chang TY; Park SC; Sohn DK; Oh JH; Park JW; Ryoo SB; Jeong SY; Park KJ
Ann Surg Oncol; 2014 Jul; 21(7):2280-7. PubMed ID: 24604580
[TBL] [Abstract][Full Text] [Related]
7. Is final TNM staging a predictor for survival in locally advanced rectal cancer after preoperative chemoradiation therapy?
Kuo LJ; Liu MC; Jian JJ; Horng CF; Cheng TI; Chen CM; Fang WT; Chung YL
Ann Surg Oncol; 2007 Oct; 14(10):2766-72. PubMed ID: 17551794
[TBL] [Abstract][Full Text] [Related]
8. The depth of post-treatment perirectal tissue invasion is a predictor of outcome in patients with clinical T3N1M0 rectal cancer treated with neoadjuvant chemoradiation followed by surgical resection.
Brandt WS; Yong S; Abood G; Micetich K; Walther A; Shoup M
Am J Surg; 2014 Mar; 207(3):357-60; discussion 360. PubMed ID: 24456833
[TBL] [Abstract][Full Text] [Related]
9. Biomarkers for cetuximab-based neoadjuvant radiochemotherapy in locally advanced rectal cancer.
Grimminger PP; Danenberg P; Dellas K; Arnold D; Rödel C; Machiels JP; Haustermans K; Debucquoy A; Velenik V; Sempoux C; Bracko M; Hölscher AH; Semrau R; Yang D; Danenberg K; Lenz HJ; Vallböhmer D
Clin Cancer Res; 2011 May; 17(10):3469-77. PubMed ID: 21558395
[TBL] [Abstract][Full Text] [Related]
10. CD8+ and FOXP3+ tumor-infiltrating T cells before and after chemoradiotherapy for rectal cancer.
Shinto E; Hase K; Hashiguchi Y; Sekizawa A; Ueno H; Shikina A; Kajiwara Y; Kobayashi H; Ishiguro M; Yamamoto J
Ann Surg Oncol; 2014 Jun; 21 Suppl 3():S414-21. PubMed ID: 24566864
[TBL] [Abstract][Full Text] [Related]
11. A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma.
Korkolopoulou P; Levidou G; Trigka EA; Prekete N; Karlou M; Thymara I; Sakellariou S; Fragkou P; Isaiadis D; Pavlopoulos P; Patsouris E; Saetta AA
BJU Int; 2012 Dec; 110(11 Pt C):E1237-48. PubMed ID: 23107319
[TBL] [Abstract][Full Text] [Related]
12. Can histopathologic assessment of circumferential margin after preoperative pelvic chemoradiotherapy for T3-T4 rectal cancer predict for 3-year disease-free survival?
Mawdsley S; Glynne-Jones R; Grainger J; Richman P; Makris A; Harrison M; Ashford R; Harrison RA; Osborne M; Livingstone JI; MacDonald P; Mitchell IC; Meyrick-Thomas J; Northover JM; Windsor A; Novell R; Wallace M
Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):745-52. PubMed ID: 16199310
[TBL] [Abstract][Full Text] [Related]
13. Posttreatment TNM staging is a prognostic indicator of survival and recurrence in tethered or fixed rectal carcinoma after preoperative chemotherapy and radiotherapy.
Chan AK; Wong A; Jenken D; Heine J; Buie D; Johnson D
Int J Radiat Oncol Biol Phys; 2005 Mar; 61(3):665-77. PubMed ID: 15708244
[TBL] [Abstract][Full Text] [Related]
14. Gene expression profiles of epidermal growth factor receptor, vascular endothelial growth factor and hypoxia-inducible factor-1 with special reference to local responsiveness to neoadjuvant chemoradiotherapy and disease recurrence after rectal cancer surgery.
Toiyama Y; Inoue Y; Saigusa S; Okugawa Y; Yokoe T; Tanaka K; Miki C; Kusunoki M
Clin Oncol (R Coll Radiol); 2010 May; 22(4):272-80. PubMed ID: 20117921
[TBL] [Abstract][Full Text] [Related]
15. PIK3CA mutations predict local recurrences in rectal cancer patients.
He Y; Van't Veer LJ; Mikolajewska-Hanclich I; van Velthuysen ML; Zeestraten EC; Nagtegaal ID; van de Velde CJ; Marijnen CA
Clin Cancer Res; 2009 Nov; 15(22):6956-62. PubMed ID: 19903786
[TBL] [Abstract][Full Text] [Related]
16. Role of KRAS mutation as predictor of pathologic response after neoadjuvant chemoradiation therapy for rectal cancer.
Martellucci J; Alemanno G; Castiglione F; Bergamini C; Valeri A
Updates Surg; 2015 Mar; 67(1):47-53. PubMed ID: 25702261
[TBL] [Abstract][Full Text] [Related]
17. Circulating cell-free DNA: a promising marker of pathologic tumor response in rectal cancer patients receiving preoperative chemoradiotherapy.
Agostini M; Pucciarelli S; Enzo MV; Del Bianco P; Briarava M; Bedin C; Maretto I; Friso ML; Lonardi S; Mescoli C; Toppan P; Urso E; Nitti D
Ann Surg Oncol; 2011 Sep; 18(9):2461-8. PubMed ID: 21416156
[TBL] [Abstract][Full Text] [Related]
18. Locally recurrent rectal cancer: prognostic factors and long-term outcomes of multimodal therapy.
Pacelli F; Tortorelli AP; Rosa F; Bossola M; Sanchez AM; Papa V; Valentini V; Doglietto GB
Ann Surg Oncol; 2010 Jan; 17(1):152-62. PubMed ID: 19834766
[TBL] [Abstract][Full Text] [Related]
19. Oncologic outcomes of pathologic stage I lower rectal cancer with or without preoperative chemoradiotherapy: are they comparable?
Huh JW; Kim CH; Kim HR; Kim YJ
Surgery; 2011 Nov; 150(5):980-4. PubMed ID: 21875732
[TBL] [Abstract][Full Text] [Related]
20. Tumor response and negative distal resection margins of rectal cancer after hyperthermochemoradiation therapy.
Tsutsumi S; Tabe Y; Fujii T; Yamaguchi S; Suto T; Yajima R; Morita H; Kato T; Shioya M; Saito J; Asao T; Nakano T; Kuwano H
Anticancer Res; 2011 Nov; 31(11):3963-7. PubMed ID: 22110227
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
